Gilead ends ulcerative colitis study due to futility

Gilead Sciences Inc. (NASDAQ:GILD) said it is stopping a Phase II/III study of ulcerative colitis candidate GS-5745 based on an interim futility analysis that showed "insufficient evidence of a treatment benefit" in either of two dose groups.

Gilead said the analysis, which was based on the first 150 patients of a planned 1,600-patient study, did not identify any safety concerns. ...